TSX:SIS - Post Discussion
Post by
retiredcf on Aug 20, 2023 5:05pm
Still a Fan
Although Savaria missed on revenue and EPS, things seem to be moving in the right direction. Organic growth in North America Accessibility was up 12%, and patient care also had strong growth. Does this look like a company ready to accelerate profits in the next 12 months?
Savaria's sales missed estimates by 4%, and its EPS of $0.14 missed estimates of $0.19. Revenue rose 3.3%, mostly organic revenue. EPS did rise from $0.13 last year. We agree that the underlying strength looks better than the headline numbers. Analysts still expect a nice uptick in EPS next year (from $0.71 to $0.90). We continue to view SIS positively and the miss doesn't concern us too much here. (5iResearch)
Be the first to comment on this post